Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) and decreased the price target to $9.00 from $55.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cory Jubinville, PhD has given his Buy rating due to a combination of factors that highlight both the challenges and potential of Rocket Pharmaceuticals’ RP-A501 program. Despite the recent setback involving a patient’s death linked to capillary leak syndrome (CLS) in the Danon disease program, there is cautious optimism about the future of the therapy. The issue may be related to the addition of a C3 inhibitor, and if this is confirmed, the program could be salvageable.
Importantly, RP-A501 has shown a positive risk-benefit profile at the current dose, significantly altering the disease’s progression and demonstrating durability over five years. While there is uncertainty regarding the resolution of the clinical hold and the FDA’s approach, the potential benefits for patients, who face severe outcomes without treatment, remain a strong consideration. Consequently, the price target has been adjusted to $9/share, reflecting the added uncertainty and potential delays in the program’s timeline.
According to TipRanks, Jubinville, PhD is an analyst with an average return of -12.2% and a 28.24% success rate. Jubinville, PhD covers the Healthcare sector, focusing on stocks such as Liquidia Technologies, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc.
In another report released today, BMO Capital also reiterated a Buy rating on the stock with a $30.00 price target.